For the last decade, CGRP (Calcitonin Gene-Related Peptide) has been the celebrity molecule of migraine research. It's the target of the newest, most effective drugs (monoclonal antibodies and gepants).
But CGRP doesn't just live in the head. A major study in 2025 has blown the doors open on where else this pain-signaling molecule is causing havoc. The prime suspect? Endometriosis.
The Shared Pathway
Endometriosis sufferers have long noted a correlation with migraine. Women with "endo" are far more likely to experience migraine attacks. We used to think this was just hormonal, similar to how postpartum hormonal shifts trigger migraines through estrogen withdrawal.
Now, we know it's also chemical.
Researchers found that endometriotic lesions are rich in CGRP nerve fibers. Just as CGRP causes blood vessel dilation and pain transmission in the brain's meninges, it appears to drive inflammation and pain processing in the pelvis.
Repurposing Relief
This discovery suggests a massive opportunity: Drug Repurposing.
If CGRP is a driver of endometriosis pain, then the very same CGRP inhibitors used for migraine (like Aimovig, Nurtec, or Ubrelvy) could theoretically treat endometriosis. Early anecdotes and off-label trials are already showing promise, offering hope that we might be able to treat two debilitating conditions with one stone.
It highlights a profound truth: Pain is a systemic issue. The brain and the body are not separate; they speak the same chemical language. Tracking symptoms across both conditions with one of the best apps to track migraines can help reveal these shared patterns.
If you experience both migraines and endometriosis, the this free app can help you spot connections between your symptoms. This free migraine tracker app makes it easy to track migraine triggers alongside hormonal cycles and identify overlapping patterns.